Clinical Trial: A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)

U.S., Sept. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07795814) titled 'A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)' on Aug. 26.

Brief Summary: This is a Phase 2 placebo-controlled study to evaluate the safety and tolerability of different doses of EDG-15400 in adults with heart failure with preserved ejection fraction (HFpEF).

Study Start Date: Aug. 25

Study Type: INTERVENTIONAL

Condition: Heart Failure With Preserved Ejection Fraction

Intervention: DRUG: EDG-15400 25 mg

EDG-15400 administered orally, once daily

DRUG: Placebo to match EDG-15400 25 mg or 50 mg

Placebo administered orally, once daily

DRUG: EDG-15400 50 mg

EDG-15400 adminis...